160 related articles for article (PubMed ID: 18326981)
1. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
; Karam JG; Loney-Hutchinson L; McFarlane SI
J Cardiometab Syndr; 2008; 3(1):68-9. PubMed ID: 18326981
[No Abstract] [Full Text] [Related]
2. High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
[TBL] [Abstract][Full Text] [Related]
3. Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Fitchett DH; Goodman SG; Langer A
Can J Cardiol; 2008 Sep; 24(9):705-8. PubMed ID: 18787721
[TBL] [Abstract][Full Text] [Related]
4. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
[TBL] [Abstract][Full Text] [Related]
5. Statin therapy after stroke or transient ischemic attack.
Cohen JS
N Engl J Med; 2006 Nov; 355(22):2368; author reply 2370-1. PubMed ID: 17135593
[No Abstract] [Full Text] [Related]
6. Statin therapy after stroke or transient ischemic attack.
Khan NA
N Engl J Med; 2006 Nov; 355(22):2369; author reply 2370-1. PubMed ID: 17139773
[No Abstract] [Full Text] [Related]
7. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
[TBL] [Abstract][Full Text] [Related]
8. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Schwartz GG; Chaitman BR; Goldberger JJ; Messig M
Am Heart J; 2011 May; 161(5):993-9. PubMed ID: 21570534
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Huisa BN; Stemer AB; Zivin JA
Vasc Health Risk Manag; 2010 Apr; 6():229-36. PubMed ID: 20407630
[TBL] [Abstract][Full Text] [Related]
10. Statin therapy after stroke or transient ischemic attack.
East JE
N Engl J Med; 2006 Nov; 355(22):2368-9; author reply 2370-1. PubMed ID: 17139775
[No Abstract] [Full Text] [Related]
11. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
[TBL] [Abstract][Full Text] [Related]
12. High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
Khan M; Kamran KA
J Pak Med Assoc; 2010 Jun; 60(6):505-6. PubMed ID: 20527658
[No Abstract] [Full Text] [Related]
13. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Mascitelli L; Pezzetta F; Goldstein MR; Chaturvedi S
Neurology; 2009 Jul; 73(3):249; author reply 249-50. PubMed ID: 19620618
[No Abstract] [Full Text] [Related]
14. [High dosage stain protects heart and brain from recurrence].
MMW Fortschr Med; 2008 Nov; 150(48):118-9. PubMed ID: 19125516
[No Abstract] [Full Text] [Related]
15. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
[TBL] [Abstract][Full Text] [Related]
16. Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Clearfield M
Curr Atheroscler Rep; 2006 Jan; 8(1):9-10. PubMed ID: 16455007
[No Abstract] [Full Text] [Related]
17. Intensive lipid lowering with atorvastatin in coronary disease.
Southern W
N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003831
[No Abstract] [Full Text] [Related]
18. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
Schwertz DW; Badellino KO
J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
[TBL] [Abstract][Full Text] [Related]
19. Intensive statin therapy--a sea change in cardiovascular prevention.
Topol EJ
N Engl J Med; 2004 Apr; 350(15):1562-4. PubMed ID: 15007111
[No Abstract] [Full Text] [Related]
20. Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
Clearfield M
Curr Atheroscler Rep; 2006 Jan; 8(1):7-8. PubMed ID: 16455005
[No Abstract] [Full Text] [Related]
[Next] [New Search]
